pharmaphorum February 12, 2024
Phil Taylor

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC), which has been filed for approval in the US.

The FDA is due to deliver a verdict on seladelpar – which was also in development for non-alcoholic steatohepatitis (NASH) before it failed a phase 3 programme – by 14th August after a priority review. It has been filed for the second-line treatment of adult PBC patients, without cirrhosis or with compensated cirrhosis, who do not respond or are intolerant to ursodeoxycholic acid (UDCA).

The $32.50-per-share offer is a 26.5% premium to CymaBay’s share price on Friday. Trading in the stock was suspended in the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article